<scp>PARADIGM</scp>‐<scp>HF</scp> Trial: Secondary Analyses Address Unanswered Questions
Kristin R. Smith(University of North Carolina at Chapel Hill), Jo E. Rodgers(Loyola University Medical Center), Orly Vardeny(University of Minnesota), Theodore J. Berei(UW Health University Hospital), Ian B. Hollis(University of North Carolina Hospitals), Chia‐Chi Hsu(National Taiwan University Hospital), Ahmed Aldemerdash(King Saud University)
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
December 19, 2017
Cited by 13
Related Papers
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2024|693
Recognition and Initial Management of Fulminant Myocarditis
|Circulation|2020|593
The genome sequence of the orchid Phalaenopsis equestris
|Nature Genetics|2014|511
2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure
|Journal of Cardiac Failure|2022|406
Role of mitochondrial dysfunction in cancer progression
|Experimental Biology and Medicine|2016|313